Choline contributes to normal liver function in the fetus and exclusively breastfed infants

On June 22, 2023, the European Authority (EFSA) published a scientific opinion recognizing the contribution of choline to the normal hepatic function of the fetus and exclusively breastfed infants. She recognized the scientific basis of this effect on health following the request for a health claim on this subject.

Extension of conditions of use of the novel food ‘astaxanthin-rich oleoresin from Haematococcus pluvialis algae’ in the EU

On 1 August 2023, the EU Commission published implementing Regulation (EU) 2023/1581 amending Implementing Regulation (EU) 2017/2470 as regards the conditions of use of the novel food ‘astaxanthin-rich oleoresin from Haematococcus pluvialis algae’. The new Regulation extends the conditions of use in food supplements for children aged 3 to less than 10 years and for adolescents aged 10 to less than 14 years of age (1).

The use of the term probiotic in France, Italy and Spain: a comparative analysis

Since the beginning of 2023, it is possible to use the word probiotic on food supplements in France. Here follows a comparison with the situation in Italy and in Spain.

Italy plans the prohibition of cultured meat

The bill, which contains provisions banning the production and marketing of animal cell-based cultured food and feed, was proposed by the Minister of Agriculture, Food Sovereignty and Forestry and the Minister of Health, and approved by the Council of Ministers.

Nutri-Score calculation changes for beverages

The right to use Nutri-Score is optional and free. It was implemented for the first time in France in 2017, based on the work of the team of Pr. Serge Hercberg as well as the expertise of the National Health Security Agency (ANSES) and the High Council of Public Health (HCSP). Since its launch in France, several countries have decided to recommend its use: Belgium, Switzerland, Germany, Spain, the Netherlands and Luxembourg. The logo is awarded on the basis of a score taking into account, for 100 g or 100 mL of product, the content: of nutrients and foods to promote (fibers, proteins, fruits, vegetables, legumes, nuts, rapeseed oil , nuts and olives) and nutrients to limit (energy, saturated fatty acids, sugars, salt). The Nutri-Score of drinks has been modified.

Health and nutrition claims in infant formulas

An international cross-sectional study recently published in the British Medical Journal found that infant diet products communicated from 1 to 4 health and nutrition claims. The authors pointed out that 2/3 of the products with at least one claim did not provide any reference. When registered clinical studies were referenced, the authors noted a high risk of bias.

Transfer of competence from the DGCCRF to the DGAL: what changes for food supplements

Starting from 2023, some food law aspects previously managed by the DGCCRF are transferred to the DGAL. What are the practical consequences for food supplements?

CBD in France

The cannabidiol, CBD, an active substance most often of natural origin, is one of the phyto-cannabinoids. CBD, as the tétrahydrocannabinol (THC ), is present in the cannabis flowers and leaves. It is a non-addictive psychotropic drug, unlike THC. It is also a component in the form of an extract, medicine, or everyday consumer products, only some of which are authorised in France under specific conditions of THC content. In addition, CBD is considered at European level as a novel food whose safety is currently being assessed by EFSA.

AGEC law: which requirements in 2023?

The law on the fight against waste and the circular economy (AGEC) of 2020 lays down provisions which will be phased in over time. We discuss the ones that will have an impact on the agri-food sector in 2023.

CBD in the U.S.: Food and dietary supplement status not appropriate

Following an exploration of potential regulatory pathways for cannabidiol (CBD) products by an internal Food and Drug Administration (FDA) working group, the FDA concluded on January 26, 2023, that a new regulatory pathway for CBD is needed to provide the regulatory oversight necessary to manage risk. The Agency is prepared to work with Congress on this issue.